Akkermansia papers

Forum thread gets too long, papers get lost in the tread.

Four papers, a good overview on Akkermansia.

Akkermansia

“The activity of Akkermansia is of relevance to susceptibility to effects of bacterial pathogens in the gut (at least in a germ-free mouse model) (Ganesh et al., 2013) as well as possible effects on protection against various intestinal and metabolic diseases described below.”

https://www.sciencedirect.com/topics/immunology-and-microbiology/akkermansia

"Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms"

Abstract

Ever since Akkermansia muciniphila was discovered and characterized two decades ago, numerous studies have shown that the lack or decreased abundance of this commensal bacterium was linked with multiple diseases (such as obesity, diabetes, liver steatosis, inflammation and response to cancer immunotherapies). Although primarily based on simple associations, there are nowadays an increasing number of studies moving from correlations to causality. The causal evidence derived from a variety of animal models performed in different laboratories and recently was also recapitulated in a human proof-of-concept trial. In this Review, we cover the history of the discovery of A. muciniphila and summarize the numerous findings and main mechanisms of action by which this intestinal symbiont improves health. A comparison of this microorganism with other next-generation beneficial microorganisms that are being developed is also made.

Key points

  • A lower abundance of Akkermansia muciniphila has been associated with multiple diseases in both mouse models and in humans.
  • A. muciniphila has proven efficacy to improve obesity, type 2 and type 1 diabetes mellitus, hepatic steatosis, intestinal inflammation and different cancers (colon cancer, response to immune checkpoints) in mice.
  • Numerous mechanisms linking A. muciniphila, specific metabolites or membrane proteins and host cell types or receptors have been identified.
  • Pasteurized A. muciniphila MucT is more efficient than the live bacterium and has proven safety and efficacy in numerous studies in mice and in a proof-of-concept study in humans.
  • A. muciniphila contributes to the maintenance of a healthy gut barrier, thereby regulating immunity, and also limits the onset of inflammation, which is the root cause of numerous diseases.

https://www.nature.com/articles/s41575-022-00631-9

3 Likes